Flynn Pharma ‘paralyzed’ by UK drug-pricing litigation, UK appeal court told
Flynn Pharma has been “paralyzed” by ongoing UK antitrust litigation over pricing of an epilepsy treatment, the British drugmaker told a UK appeal court. A three-day hearing at the court wrapped...To view the full article, register now.
Already a subscriber? Click here to view full article